Aims Evaluate the effects of once‐weekly subcutaneous semaglutide 2.4 mg on
cardiometabolic risk factors in people with overweight/obesity without diabetes in the STEP …

Abstract Objective In the Semaglutide Treatment Effect in People with obesity (STEP) trials,
once‐weekly subcutaneous semaglutide 2.4 mg plus lifestyle intervention reduced body …

Objective This study assessed the effects of semaglutide on body weight, cardiometabolic
risk factors, and glycemic status in individuals categorized by baseline BMI with or without …

Background: The 2-year efficacy and safety of once-weekly (OW) subcutaneous semaglutide
2.4 mg vs placebo in adults with overweight/obesity was assessed in the STEP 5 phase 3 …

Abstract Background/Objective There are limited real-world studies assessing semaglutide
weight loss and associated comorbidity and metabolic outcomes over periods≥ 6 months …

Background Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …

Objective This paper describes the baseline characteristics of the Semaglutide Effects on
Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) study, one of the …

In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major
adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease …

Background Obesity is a global health challenge with few pharmacologic options. Whether
adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 …

Cardiovascular disease (CVD) is a major cause of morbidity and mortality. Although it has
been widely appreciated that obesity is a major risk factor for CVD, treatments that produce …